Greywolf Therapeutics

Greywolf Therapeutics

UK - Oxford
Biotechnology

Focus: Modulating ERAP1 and ERAP2 in immuno-oncology

Greywolf Therapeutics is a life sciences company focused on Modulating ERAP1 and ERAP2 in immuno-oncology.

Oncology
Funding Stage
SERIES B
Total Funding
$131M
Open Jobs
4